Jamjoom Pharmaceuticals Factory Company (4015.SR) — Financial statements
Income statement, balance sheet, and cash flow for Jamjoom Pharmaceuticals Factory Company — annual and quarterly history with growth and margin analysis.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,501↑13.8% | 1,318↑19.8% | 1,101↑20.1% | 917↑24.6% | 736 | |
| Cost of Revenue | 562↑12.8% | 498↑24.8% | 399↑23.6% | 323↑23.7% | 261 | |
| Gross Profit | 939↑14.4% | 821↑16.9% | 702↑18.2% | 594↑25.1% | 475 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00↓100.0% | 34↑1.8% | 33↑2.2% | 33↓11.7% | 37 | |
| General & Administrative Expenses | 0.00↓100.0% | 28↓1.9% | 29↑45.8% | 20↑33.2% | 15 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 184↑13.3% | 163↑7.5% | 152↑23.3% | 123 | |
| SG&A Expenses | 0.00↓100.0% | 213↑11.0% | 191↑11.9% | 171↑24.3% | 138 | |
| Other Expenses | 464↑140.6% | 193↑7615.1% | 3↓48.3% | 5↑8.2% | 4 | |
| Operating Expenses | 464↑5.6% | 439↑13.1% | 388↑10.8% | 351↑21.4% | 289 | |
| Total Costs & Expenses | 1,026↑9.4% | 937↑19.0% | 787↑16.9% | 673↑22.5% | 550 | |
| Operating Results | ||||||
| Operating Income | 475↑24.6% | 381↑21.6% | 313↑34.3% | 233↑24.9% | 187 | |
| Depreciation & Amortization | 0.00↓100.0% | 37↑40.5% | 27↑7.7% | 25↑1.5% | 24 | |
| EBITDA | 475↑13.0% | 420↑22.7% | 343↑62.2% | 211↓0.7% | 213 | |
| EBIT | 475↑24.0% | 383↑21.2% | 316↑69.4% | 186↓0.9% | 188 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 6↑1099.5% | -0.63↑27.1% | -0.86↑72.9% | -3 | |
| Interest Income | 0.00↓100.0% | 6 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 0.10↓83.8% | 0.63↑413.0% | 0.12↓96.2% | 3 | |
| Non-Operating Income | 0.00↑100.0% | -2↑34.2% | -3↓105.4% | 47↑3353.4% | -1 | |
| Other Income / Expenses | -475↓30442.1% | 2↓35.3% | 2↑105.1% | -47↓3626.3% | 1 | |
| Income Before Tax | 0.00↓100.0% | 383↑21.2% | 316↑69.5% | 186↓0.9% | 188 | |
| Income Tax Expense | 0.00↓100.0% | 26↑11.7% | 23↑56.0% | 15↓13.7% | 17 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 0.00↓100.0% | 357↑21.9% | 292↑70.4% | 172↑0.5% | 171 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 464↑30.1% | 357↑21.9% | 292↑70.7% | 171↑0.4% | 171 | |
| Bottom-Line Net Income | 464↑30.1% | 357↑21.9% | 292↑70.7% | 171↑0.4% | 171 | |
| EPS (Basic) | 6.60↑29.4% | 5.10↑22.0% | 4.18↑70.6% | 2.45↑0.4% | 2.44 | |
| EPS (Diluted) | 6.60↑29.4% | 5.10↑22.0% | 4.18↑70.6% | 2.45↑0.4% | 2.44 | |
| Weighted Average Shares | 70↑0.4% | 70↑0.0% | 70↑0.0% | 70↑0.0% | 70 | |
| Weighted Average Diluted Shares | 70↑0.4% | 70↑0.0% | 70↑0.0% | 70↑0.0% | 70 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.